Merck & Co (MRK) Aktie Kurs
Merck & Co Kurs
Omsætningen er vokset med 5,7 % om året de seneste 19 år til 64,93 Mrd. USD. Indtjening pr. aktie er vokset med 7,0 % om året de seneste 19 år. Merck & Cos nettoavance ligger på 28,1 %, op fra 26,8 % for flere år siden. Merck & Co har i øjeblikket et direkteafkast på omkring 2,21 %. Udlodningsandelen er omkring 45 % af indtjeningen. Udbyttet er vokset med 4,1 % om året de seneste 19 år. Analytikernes mediankursmål er 144,00 USD, hvilket er under den aktuelle kurs med 3,1 %. Af 35 analytikere anbefaler 26 køb — den samlede vurdering er Køb.
Merck & Co aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Merck & Co aktie og aktieanalyse
Hyppigt stillede spørgsmål om Merck & Co-aktien
The business model of Merck & Co Inc is centered around the development, manufacturing, and marketing of innovative pharmaceutical products and vaccines. Merck's primary aim is to improve and save lives by addressing unmet medical needs. Through rigorous research and development, the company focuses on discovering novel therapies and delivering them to patients worldwide. Merck operates across various therapeutic areas, including oncology, infectious diseases, vaccines, cardiovascular health, and more. By combining scientific expertise with a strong commitment to patients and healthcare professionals, Merck continually strives to advance medical science and make a positive impact on global health.
Merck & Co Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Merck & Co Inc in the market are Johnson & Johnson, Pfizer Inc, Novartis AG, and Bristol-Myers Squibb Company.
Merck & Co Inc is a renowned pharmaceutical company with a rich history and notable background. Established in 1891, Merck & Co Inc has been dedicated to enhancing global health and improving people's lives. The company has evolved into one of the leading players in the pharmaceutical industry, specializing in research, development, and manufacturing of innovative medications and vaccines. Merck & Co Inc has proactively contributed to medical advancements, from pioneering treatments for diseases like HIV/AIDS to addressing various health challenges. With a commitment to scientific excellence and patient well-being, Merck & Co Inc continues to shape the future of healthcare worldwide.
Merck & Co Inc, a leading pharmaceutical company, has achieved significant milestones throughout its history. The company's notable achievements include the development and launch of groundbreaking drugs like Gardasil, a vaccine for preventing cervical cancer, and Keytruda, an innovative immunotherapy for treating various types of cancer. Merck & Co Inc has also contributed to medical advancements with its research and development efforts, resulting in breakthroughs in areas such as HIV/AIDS treatment and vaccines. The company's commitment to improving global health has resulted in partnerships and initiatives aimed at tackling diseases like malaria and Ebola. Merck & Co Inc continues to make strides in the pharmaceutical industry, focusing on innovative solutions for unmet medical needs.
Merck & Co Inc is primarily present in several countries and regions across the world. The company has a strong global presence, with operations in the United States, Europe, Asia-Pacific, Latin America, and Africa. Merck & Co Inc has established a significant presence in key markets such as the United States, Germany, Japan, China, and Brazil. With its wide international footprint, Merck & Co Inc is committed to delivering its innovative healthcare solutions to patients and healthcare professionals worldwide.
Merck & Co Inc represents a strong commitment to scientific innovation, integrity, and improving global health. As a leading pharmaceutical company, Merck aims to discover, develop, and provide high-quality healthcare solutions. The company's corporate philosophy revolves around putting patients first, valuing diversity and inclusion, and taking responsibility for environmental sustainability. Merck is dedicated to delivering innovative medicines and vaccines, ensuring affordability and access for patients worldwide. With a focus on research, collaboration, and ethical business practices, Merck strives to make a positive impact on society and enhance the well-being of individuals around the globe.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 140,42 USD for Merck & Co-aktien (median: 144,00 USD), svarende til -3,2 % i forhold til seneste kurs. Konsensus bygger på 35 analytikervurderinger.
35 analytikere vurderer i øjeblikket Merck & Co-aktien: 26 anbefaler køb, 9 hold og 0 salg. For 2026 forventer analytikere, at Merck & Co genererer omsætning på 67,04 Mrd. USD og indtjening pr. aktie på 2,67 USD.
Omregnet til den aktuelle valutakurs handles Merck & Co-aktien til 132,24 EUR (148,54 USD).
Merck & Co-aktien (MRK) er noteret på 11 børser, herunder: NYSE (MRK), London (0QAH.L), SIX (Zürich) (MRK1.SW), XETRA (6MK.DE), Frankfurt (6MK.F), München (6MK.MU), Düsseldorf (6MK.DU), Hamburg (6MK.HM).
Merck & Co Inc is one of the leading global pharmaceutical companies focused on the discovery, development, and marketing of drugs, vaccines, and biologics for a variety of diseases and disorders. The company is headquartered in Kenilworth, New Jersey and operates worldwide in over 140 countries.
forventet-omsætningen for Merck & Co er 67,04 Mrd. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Merck & Co er 6,64 Mrd. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Merck & Co er i øjeblikket 55,68. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Merck & Co-aktien.
Pris-til-salgs-forholdet (P/S) for Merck & Co er i øjeblikket 5,51. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Merck & Co-aktien.
AlleAktien-kvalitetsscore for Merck & Co er 6/10.
ISIN for Merck & Co er US58933Y1055. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Merck & Co er A0YD8Q. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Merck & Co er MRK. Tickersymbolet bruges til at handle Merck & Co-aktier på børsen.
Merck & Co aktie
Merck & Co Peer Group
Merck & Co Ticker
Merck & Co FIGI
Alle fundamentale data om Merck & Co i deep dive
Vores aktieanalyse af Merck & Co-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Merck & Co. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: